GlassScriptPhysician profile
Fozia Chatta
NPI 1659309953
$7,446.20
in general payments reported to CMS, 2019-2025
37 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $661 · 2021: $795 · 2022: $1,165 · 2023: $1,238 · 2024: $1,121 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,610 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,610.21 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,201.63 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $885.89 | 2021-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $751.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $642.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $408.90 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $377.23 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $322.84 | 2023-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $283.99 | 2019-2025 | |
| Amgen INC. | $245.75 | 2019-2025 | Repatha, Otezla, Otezla |
| Kowa Pharmaceuticals America, INC. | $206.78 | 2019-2025 | Livalo, Zoryve, Seglentis |
| Janssen Pharmaceuticals, INC | $189.19 | 2019-2024 | Xarelto |
| Daiichi Sankyo INC. | $167.22 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $161.59 | 2019-2023 | Verquvo, Belsomra |
| Abbott Laboratories | $159.40 | 2021-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Astellas Pharma US INC | $149.95 | 2019-2025 | Veozah |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fozia Chatta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.